A Phase 3 interventional study of Ranibizumab and Port Delivery System with Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD), sponsored by Hoffmann-La Roche. Active, not recruiting at 104 sites in 16 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 16th largest by enrollment of the 124 interventional ones that give a count, is one of 4 that started in 2021, is one of 31 in phase 3, and was the 115th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 451 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
32 studies in Macular Degeneration by Hoffmann-La Roche: 3 open now, 10 under way, 4 of them phase 3. Of 21 finished, 10 (48%) have results posted.
Among the 32 studies in Macular Degeneration by Hoffmann-La Roche, this one is the 8th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2021, is one of 14 in phase 3, and was the 20th registered.
Hoffmann-La Roche’s Macular Degeneration studies by the year they started, since 2002.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
Among Hoffmann-La Roche’s 32 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokinetics of the Port Delivery System with ranibizumab (PDS) 100 mg/mL delivered every 36 weeks (Q36W) compared with every 24 weeks (Q24W) in patients with neovascular age-related macular degeneration (nAMD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to the Q36W arm will receive PDS implant refill-exchange procedures (ranibizumab 100 mg/mL) on a Q36W fixed interval.
Drug: Ranibizumab · Device: Port Delivery System with Ranibizumab
Participants randomized to the Q24W arm will receive PDS implant refill-exchange procedures (ranibizumab 100 mg/mL) on a Q24W fixed interval.
Drug: Ranibizumab · Device: Port Delivery System with Ranibizumab
Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals
Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals
Change from baseline in Best-corrected visual acuity (BCVA) score averaged over Weeks 68 and 72, as assessed using the ETDRS chart starting at a distance of 4 meters
EDTRS = Early Treatment Diabetic Retinopathy Study. A vision score of 20/20 vision is considered normal. A score of 20/200 is considered being legally blind.
Time frame: Baseline to Week 72
Change from baseline in BCVA score over time
Time frame: Baseline up to Week 72
Percentage of participants with BCVA score of 69 letters (approximate 20/40 Snellen equivalent) or better averaged over Weeks 68 and 72
Time frame: Baseline to Week 72
Percentage of participants with BCVA score of 69 letters (approximate 20/40 Snellen equivalent) or better over time
Time frame: Baseline up to Week 72
Percentage of participants with BCVA score of 38 letters (approximate 20/200 Snellen equivalent) or worse averaged over Weeks 68 and 72
Time frame: Baseline to Week 72
Percentage of participants with BCVA score of 38 letters (approximate 20/200 Snellen equivalent) or worse over time
Time frame: Baseline up to Week 72
Percentage of participants who report preferring ranibizumab 100 mg/mL delivered via the PDS compared with intravitreal treatment, as measured by the PDS Patient Preference Questionnaire (PPPQ) at At Weeks 24, 40 and 72
Time frame: At Weeks 24, 40, 72
Percentage of participants with bilateral disease who report preferring ranibizumab 100 mg/mL delivered via the PDS compared with intravitreal treatment, as measured by the PPPQ at At Weeks 24, 40 and 72
Time frame: At Weeks 24, 40, 72
Mean overall treatment satisfaction at Week 40, as measured by the Macular Disease Treatment Satisfaction Questionnaire (MacTSQ) total score in the Q36W arm compared with the Q24W arm
Time frame: At Week 40
Percentage of participants who lose <10, <5, or gain >= 0 letters in BCVA score from baseline averaged over Weeks 68 and 72
Time frame: Baseline to Week 72
Percentage of participants who lose <10, <5, or gain >= 0 letters in BCVA score from baseline over time
Time frame: Baseline up to Week 72
Incidence and severity of ocular and systemic (non-ocular) adverse events in the Q36W and Q24W arms
Time frame: Baseline up to Week 72
Incidence, severity, and duration of adverse events of special interest, including ocular adverse events of special interest in the Q36W and Q24W arms
Time frame: Baseline up to Week 72
Incidence, severity, and duration of ocular adverse events of special interest during the postoperative period (≤ 37 days of initial implantation) and follow-up period (> 37 days after implantation surgery) in all enrolled participants
Time frame: Baseline up to Week 72
Incidence and severity of adverse device effects in the Q36W and Q24W arms
Time frame: Baseline up to Week 72
Incidence, causality, severity, and duration of anticipated serious adverse device effects in the Q36W and Q24W arms
Time frame: Baseline up to Week 72
Change from baseline in center point thickness (CPT) up to and including Week 72
Time frame: Baseline up to Week 72
Percentage of participants who do not undergo supplemental treatment with intravitreal ranibizumab 0.5 mg before each refill-exchange procedure
Time frame: Week 16 to Week 68
Observed serum concentration of ranibizumab at specified timepoints
Time frame: Baseline to Week 72
Incidence of treatment-emergent ADAs during the study
Time frame: Baseline to Week 72
Showing the first 100 of 104 sites across 16 countries. Choose a country and city above to see the rest.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
No publications or documents are linked to this record.
Started Jul 2021 (actual). Primary completion is estimated for Feb 2027, 66 months after the start.
Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 66 months is above that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab